Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2025
Reporting Period: Quarterly period ended September 30, 2025
This filing serves as a notification that the Company issued a press release and an earnings presentation regarding its financial results for the quarter ended September 30, 2025. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) rather than within the body of this 8-K form.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being disclosed in the attached press release and earnings presentation.
Material Changes
No material changes or comparative financial data versus prior periods are detailed in the text of this filing. Investors must refer to the attached exhibits for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
Management Commentary: The Company released an earnings presentation (Exhibit 99.2) which typically contains management discussion, outlook, and guidance, but the specific content is not included in this text.
Risks and Contingencies: No specific risks or contingencies are enumerated in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q3 2025.
- Examine Exhibit 99.2 (Earnings Presentation) for updated clinical trial timelines, regulatory milestones, and forward-looking guidance.
- Verify the Company's cash runway and burn rate as disclosed in the attached financial statements.
- Check for any updates on the Company's primary therapeutic candidates or pipeline developments mentioned in the presentation.